Search

Hai V. Nguyen

Examiner (ID: 249)

Most Active Art Unit
2649
Art Unit(s)
2152, 2142, 2618, 2649, 2647
Total Applications
1496
Issued Applications
1169
Pending Applications
146
Abandoned Applications
211

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17706006 [patent_doc_number] => 20220206012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS [patent_app_type] => utility [patent_app_number] => 17/393267 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393267 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/393267
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS Aug 2, 2021 Pending
Array ( [id] => 20264153 [patent_doc_number] => 12435129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Anti-Ab antibodies [patent_app_type] => utility [patent_app_number] => 17/383765 [patent_app_country] => US [patent_app_date] => 2021-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 49 [patent_no_of_words] => 19170 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383765 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/383765
Anti-Ab antibodies Jul 22, 2021 Issued
Array ( [id] => 18237686 [patent_doc_number] => 20230069996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => LIGAND-BINDING FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/793587 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793587 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/793587
LIGAND-BINDING FUSION PROTEINS Jul 19, 2021 Pending
Array ( [id] => 17368368 [patent_doc_number] => 20220023420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => FUSION CONSTRUCTS AND METHODS OF USING THEREOF [patent_app_type] => utility [patent_app_number] => 17/305577 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305577 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/305577
Fusion constructs and methods of using thereof Jul 8, 2021 Issued
Array ( [id] => 18550783 [patent_doc_number] => 20230248783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => METHOD AND COMPOSITION FOR ENHANCING CANCER TREATMENT EFFICACY OF BACTERIA EXTRACELLULAR VESICLES [patent_app_type] => utility [patent_app_number] => 18/012498 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012498 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/012498
METHOD AND COMPOSITION FOR ENHANCING CANCER TREATMENT EFFICACY OF BACTERIA EXTRACELLULAR VESICLES Jun 21, 2021 Pending
Array ( [id] => 17399635 [patent_doc_number] => 20220041725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Combination Therapy for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/351724 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351724 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/351724
Combination Therapy for the Treatment of Cancer Jun 17, 2021 Abandoned
Array ( [id] => 20179509 [patent_doc_number] => 20250263467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION [patent_app_type] => utility [patent_app_number] => 18/001583 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -88 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001583 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/001583
ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION Jun 10, 2021 Abandoned
Array ( [id] => 17297854 [patent_doc_number] => 20210393693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/342518 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342518 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/342518
T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof Jun 7, 2021 Pending
Array ( [id] => 19667564 [patent_doc_number] => 12180292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => CD70 binding molecules and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/328118 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 57 [patent_no_of_words] => 38265 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328118 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/328118
CD70 binding molecules and methods of use thereof May 23, 2021 Issued
Array ( [id] => 18707643 [patent_doc_number] => 20230330222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTS [patent_app_type] => utility [patent_app_number] => 17/998733 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998733 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/998733
SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTS May 13, 2021 Pending
Array ( [id] => 17067285 [patent_doc_number] => 20210269500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => CELL SURFACE COUPLING OF NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/318590 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318590 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/318590
Cell surface coupling of nanoparticles May 11, 2021 Issued
Array ( [id] => 19840178 [patent_doc_number] => 12252547 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same [patent_app_type] => utility [patent_app_number] => 17/317824 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 76 [patent_no_of_words] => 28186 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317824 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/317824
Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same May 10, 2021 Issued
Array ( [id] => 17168805 [patent_doc_number] => 20210322475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/307158 [patent_app_country] => US [patent_app_date] => 2021-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307158 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/307158
COMPOSITIONS AND METHODS FOR TREATING CANCER May 3, 2021 Abandoned
Array ( [id] => 18434461 [patent_doc_number] => 20230181755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL [patent_app_type] => utility [patent_app_number] => 17/916737 [patent_app_country] => US [patent_app_date] => 2021-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916737 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/916737
ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL Apr 21, 2021 Pending
Array ( [id] => 18529970 [patent_doc_number] => 20230235037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => METHOD OF TREATMENT USING ANTI-CCL24 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/996386 [patent_app_country] => US [patent_app_date] => 2021-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996386 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/996386
METHOD OF TREATMENT USING ANTI-CCL24 ANTIBODY Apr 19, 2021 Pending
Array ( [id] => 17336099 [patent_doc_number] => 20220002430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => IMMUNOGLOBULIN VARIANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/235805 [patent_app_country] => US [patent_app_date] => 2021-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17235805 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/235805
IMMUNOGLOBULIN VARIANTS AND USES THEREOF Apr 19, 2021 Abandoned
Array ( [id] => 18352583 [patent_doc_number] => 20230140694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => COMBINATION TREATMENT FOR CANCER INVOLVING ANTI-ICOS AND ANTI-PD1 ANTIBODIES, OPTIONALLY FURTHER INVOLVING ANTI-TIM3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/911937 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911937 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/911937
COMBINATION TREATMENT FOR CANCER INVOLVING ANTI-ICOS AND ANTI-PD1 ANTIBODIES, OPTIONALLY FURTHER INVOLVING ANTI-TIM3 ANTIBODIES Apr 11, 2021 Abandoned
Array ( [id] => 17213174 [patent_doc_number] => 20210346510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => Tetravalent Antibody-Drug Conjugates and Use Thereof [patent_app_type] => utility [patent_app_number] => 17/227536 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10146 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227536 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/227536
Tetravalent antibody-drug conjugates and use thereof Apr 11, 2021 Issued
Array ( [id] => 18420210 [patent_doc_number] => 20230174671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/917726 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917726 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/917726
COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS Apr 8, 2021 Pending
Array ( [id] => 18657752 [patent_doc_number] => 20230303706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => MONOCYTE [patent_app_type] => utility [patent_app_number] => 17/995815 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995815 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/995815
MONOCYTE Apr 8, 2021 Pending
Menu